Evidence map›Paper›PMID 33468486›Full record

ArticleAntimicrobial agents and chemotherapy2021

The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an

Maria-Ioanna Beredaki, Maiken Cavling Arendrup, David Andes, Johan W Mouton, Joseph Meletiadis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Assessment of Antifungal Pharmacodynamics.Journal of fungi (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Maria-Ioanna BeredakiClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maiken Cavling ArendrupUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-4747-0144
David AndesUniversity of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0002-7927-9950
Johan W MoutonDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece jmeletiadis@med.uoa.gr.ORCID 0000-0002-8869-1509
National and Kapodistrian University of Athens · GRErasmus MC · NLStatens Serum Institut · DKUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posaconazole is more active than fluconazole against

Indexed as

Antifungal AgentsCandida albicansAnimalsCandidaMicrobial Sensitivity TestsTriazolesAntifungal AgentsposaconazoleTriazolesbreakpointsCandida albicanscandidiasisCLSIEUCASTMonte Carlo simulationpharmacokinetic-pharmacodynamicPK/PD susceptibility breakpointsposaconazoletherapeutic drug monitoring

Identifiers

PMID33468486
PMCPMC8097413
OpenAlexW3123253611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.